The adoption of continuous glucose monitoring (CGM) and insulin pump therapy in the everyday life of children and adolescents with T1D is a real innovation and the most promising choice for optimizing glycemic control in this population [1,2]. This evidence concerns the gene INS and type 1 diabetes mellitus.